Published in BMC Med Genet on June 26, 2011
Microhomology-mediated mechanisms underlie non-recurrent disease-causing microdeletions of the FOXL2 gene or its regulatory domain. PLoS Genet (2013) 1.16
Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb) (2012) 0.81
Involvement of a citrus meiotic recombination TTC-repeat motif in the formation of gross deletions generated by ionizing radiation and MULE activation. BMC Genomics (2015) 0.78
Deletion of exon 8 from the EXT1 gene causes multiple osteochondromas (MO) in a family with three affected members. Springerplus (2016) 0.78
Bilateral Scapulothoracic Osteochondromas in a Patient With Hereditary Multiple Exostosis: A Case Report and Review of the Literature. Orthop Rev (Pavia) (2016) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Nonviral retroposons: genes, pseudogenes, and transposable elements generated by the reverse flow of genetic information. Annu Rev Biochem (1986) 11.03
Alu repeats and human disease. Mol Genet Metab (1999) 6.64
A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genet (2009) 6.39
MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet (2008) 6.00
The mechanism of human nonhomologous DNA end joining. J Biol Chem (2007) 5.02
Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet (2004) 4.47
Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases. Hum Mol Genet (2007) 4.07
The natural history of hereditary multiple exostoses. J Bone Joint Surg Am (1994) 3.88
Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand breaks lacking overlapping end sequences. Mol Cell Biol (2003) 3.32
Human genomic deletions mediated by recombination between Alu elements. Am J Hum Genet (2006) 3.15
Translocation and gross deletion breakpoints in human inherited disease and cancer I: Nucleotide composition and recombination-associated motifs. Hum Mutat (2003) 2.55
Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet (1995) 2.29
Hereditary multiple exostoses. J Med Genet (1991) 2.19
Natural history study of hereditary multiple exostoses. Am J Med Genet (1995) 2.09
Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat (2004) 1.94
The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet (1996) 1.87
Genomic rearrangements in inherited disease and cancer. Semin Cancer Biol (2010) 1.72
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet (1999) 1.70
Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat (2009) 1.61
Alu recombination-mediated structural deletions in the chimpanzee genome. PLoS Genet (2007) 1.59
Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet (1996) 1.58
Molecular dissection of a contiguous gene syndrome: localization of the genes involved in the Langer-Giedion syndrome. Hum Mol Genet (1995) 1.51
Useful 'junk': Alu RNAs in the human transcriptome. Cell Mol Life Sci (2007) 1.50
A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A (2009) 1.47
Delineation of a contiguous gene syndrome with multiple exostoses, enlarged parietal foramina, craniofacial dysostosis, and mental retardation, caused by deletions in the short arm of chromosome 11. Am J Hum Genet (1996) 1.23
Langer-Giedion syndrome. Birth Defects Orig Artic Ser (1974) 1.17
Genomic organization and promoter structure of the human EXT1 gene. Genomics (1997) 1.15
Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements. Am J Hum Genet (2008) 1.12
NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet (1998) 1.11
The structure of the human multiple exostoses 2 gene and characterization of homologs in mouse and Caenorhabditis elegans. Genome Res (1997) 1.03
Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. Hum Mutat (2010) 1.03
SINEs point to abundant editing in the human genome. Genome Biol (2005) 0.97
Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA". J Pediatr Orthop (2007) 0.90
Proximal chromosome 11p contiguous gene deletion syndrome phenotype: case report and review of the literature. Clin Neuropathol (2007) 0.87
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science (2011) 3.29
The clinical approach towards chondrosarcoma. Oncologist (2008) 3.01
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet (2011) 2.74
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase. Am J Hum Genet (2006) 2.31
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Technical considerations in CT-guided radiofrequency thermal ablation of osteoid osteoma: tricks of the trade. AJR Am J Roentgenol (2002) 2.10
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer (2005) 2.01
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol (2009) 1.96
Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat (2004) 1.94
Copy number variation in regions flanked (or unflanked) by duplicons among patients with developmental delay and/or congenital malformations; detection of reciprocal and partial Williams-Beuren duplications. Eur J Hum Genet (2006) 1.93
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol (2010) 1.91
Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem (2007) 1.88
Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol (2003) 1.85
Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. Am J Hum Genet (2003) 1.79
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Lymphatics and bone. Hum Pathol (2007) 1.76
Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet (2002) 1.72
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer (2010) 1.63
Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol (2009) 1.63
The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol (2007) 1.61
Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat (2009) 1.61
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol (2011) 1.61
Guidelines for molecular karyotyping in constitutional genetic diagnosis. Eur J Hum Genet (2007) 1.56
Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood (2008) 1.56
A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer (2010) 1.56
Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist (2011) 1.54
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res (2008) 1.51
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol (2009) 1.48
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet (2007) 1.46
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol (2010) 1.43
Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies. Am J Hum Genet (2011) 1.41
Hypoparathyroidism-retardation-dysmorphism syndrome in a girl: A new variant not caused by a TBCE mutation--clinical report and review. Am J Med Genet A (2006) 1.40
Real-time monitoring of rolling-circle amplification using a modified molecular beacon design. Nucleic Acids Res (2002) 1.39
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst (2007) 1.37
Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet (2011) 1.34
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging (2002) 1.33
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest (2011) 1.32
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res (2009) 1.31
Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology (2004) 1.31
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol (2005) 1.30
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics (2007) 1.24
The spectra of clinical phenotypes in aplasia cutis congenita and terminal transverse limb defects. Am J Med Genet A (2009) 1.24
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells (2011) 1.23
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol (2009) 1.23
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res (2009) 1.22
Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol (2006) 1.21
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis Rheum (2007) 1.20
Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn (2002) 1.19
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer (2009) 1.18
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res (2005) 1.18
Non-coding RNA annotation of the genome of Trichoplax adhaerens. Nucleic Acids Res (2009) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hum Mutat (2004) 1.17
Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors. J Bone Joint Surg Am (2011) 1.17
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol (2005) 1.16
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol (2005) 1.15
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
A subterminal deletion of the long arm of chromosome 10: a clinical report and review. Am J Med Genet A (2006) 1.14
Rapid aneuploidy detection with multiplex ligation-dependent probe amplification: a prospective study of 4000 amniotic fluid samples. Eur J Hum Genet (2008) 1.13
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One (2012) 1.13
Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Am J Surg Pathol (2015) 1.13
Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol (2014) 1.12
Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res (2009) 1.12
Imaging mass spectrometry statistical analysis. J Proteomics (2012) 1.11
Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol (2009) 1.11
Placozoa and the evolution of Metazoa and intrasomatic cell differentiation. Int J Biochem Cell Biol (2008) 1.11
Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer (2012) 1.11
Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch (2009) 1.10